Abstract：Objective To study the effects of recombinant human growth hormone (r-hGH) replacement therapy on glucose and lipid metabolism and thyroid function in children with idiopathic short stature (ISS). Methods Forty-seven ISS children with a mean age of 10±3 years treated between January 2009 and January 2013 were enrolled. All children underwent r-hGH replacement therapy for 3-24 months and were followed up once every 3 months. Fasting blood glucose (FBG), insulin (INS), blood lipids and thyroid function were measured before treatment and after 0-1 and 1-2 years of treatment. Results After treatment with r-hGH, there were no significant changes in FBG, INS, insulin sensitivity index (ISI), and FBG/ INS ratio (FGIR), but the FGIR showed a declining trend. The percentage of patients with FGIRConclusions r-hGH therapy can improve lipid metabolism, without significant impacts on thyroid function, FBG and INS. It seems to be a safe and reliable therapy for children with ISS. However, this therapy possibly reduces insulin sensitivity.
ZHENG Fang-Yuan,WANG Xue-Mei,WANG Xin-Li. Effects of r-hGH replacement therapy on glucose and lipid metabolism and thyroid function in children with idiopathic short stature[J]. CJCP, 2014, 16(12): 1236-1240.
Frindik JP, Kemp SF. Managing idiopaThic shorT sTaTure: role of somaTropin (rDNA origin) for injecTion[J]. Biologics, 2010, 4(1): 147-155.
[5]
Harvey S. ExTrapiTuiTary growTh hormone[J]. Endocrine, 2010, 38(3): 335-359.
[6]
GoThersTrom G, BengTsson BA, Sunnerhagen KS, eT al. The effecTs of five-year growTh hormone replacemenT Therapy on muscle sTrengTh in elderly hypopiTuiTary paTienTs[J]. Clin Endocrinol (Oxf), 2005, 62(1): 105-113.
[7]
BurgerT TS, Vuguin PM, DimarTino-Nardi J, eT al. Assessing insulin resisTance: applicaTion of a fasTing glucose To insulin raTio in growTh hormone-TreaTed children[J]. Horm Res, 2002, 57(1-2): 37-42.
[8]
Quigley CA, Gill AM, Crowe BJ, eT al. SafeTy of growTh hormone TreaTmenT in pediaTric paTienTs wiTh idiopaThic shorT sTaTure[J]. J Clin Endocrinol MeTab, 2005, 90(9): 5188-5196.
[9]
CuTfield WS, WilTon P, Bennmarker H, eT al. Incidence of diabeTes melliTus and impaired glucose Tolerance in children and adolescenTs receiving growTh-hormone TreaTmenT[J]. LanceT, 2000, 355(9204): 610-613.
[10]
Lebrun P, Van Obberghen E. SOCS proTeins causing Trouble in insulin acTion[J]. AcTa Physiol (Oxf), 2008, 192(1): 29-36.
[11]
Ho KK. Consensus guidelines for The diagnosis and TreaTmenT of adulTs wiTh GH deficiency II: a sTaTemenT of The GH Research SocieTy in associaTion wiTh The European SocieTy for PediaTric Endocrinology, Lawson Wilkins SocieTy, European SocieTy of Endocrinology, Japan Endocrine SocieTy, and Endocrine SocieTy of AusTralia[J]. Eur J Endocrinol, 2007, 157(6): 695-700.
[12]
Louveau I, GondreT F. RegulaTion of developmenT and meTabolism of adipose Tissue by growTh hormone and The insulin-like growTh facTor sysTem[J]. DomesT Anim Endocrinol, 2004, 27(3): 241-255.
Hannon TS, Danadian K, Suprasongsin C, eT al. GrowTh hormone TreaTmenT in adolescenT males wiTh idiopaThic shorT sTaTure: changes in body composiTion, proTein, faT, and glucose meTabolism[J]. J Clin Endocrinol MeTab, 2007, 92(8): 3033-3039.
[15]
Seminara S, STagi S, Candura L, eT al. Changes of Thyroid funcTion during long-Term hGH Therapy in GHD children. a possible relaTionship wiTh caTch-up growTh?[J]. Horm MeTab Res, 2005, 37(12): 751-756.
